{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T07:29:48Z","timestamp":1790839788861,"version":"4.1.0"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,7,13]],"date-time":"2021-07-13T00:00:00Z","timestamp":1626134400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,7,13]],"date-time":"2021-07-13T00:00:00Z","timestamp":1626134400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Stem Cell Res Ther"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Perianal fistula is one of the most common complications in Crohn\u2019s disease, and various medical and surgical treatments are being tried. The aim of this study was to compare the perianal fistula closure rates following treatment with anti-tumor necrosis factor (TNF) agents or autologous adipose tissue-derived stem cell (auto-ASC) transplantation with Crohn\u2019s disease (CD).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>CD patients who underwent seton placement for perianal fistula from January 2015 to December 2019 at a tertiary referral center were retrospectively reviewed. Patients were divided into two groups, one that received sequential treatments with anti-TNF agents (anti-TNF group) and the other that underwent auto-ASC transplantation (stem cell group). Clinical variables and fistula closure rates were compared in the two groups.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Of the 69 patients analyzed, 39 were treated with anti-TNF agents and 30 underwent auto-ASC transplantation. Compared with the stem cell group, patients in the anti-TNF group were older (<jats:italic>p<\/jats:italic>=0.028), were more frequently male (<jats:italic>p<\/jats:italic>=0.019), had fistulas with more penetrating behavior (<jats:italic>p<\/jats:italic>=0.002), had undergone surgery more frequently (<jats:italic>p<\/jats:italic>=0.010), and had a shorter interval from seton placement to intended treatment (<jats:italic>p<\/jats:italic>&lt;0.001). During a median follow-up of 46 months (range, 30\u201352.5 months), fistula closure rates were significantly faster (83.3% vs. 23.1%, <jats:italic>p<\/jats:italic>&lt;0.001), and the mean interval from seton placement to fistula closure significantly shorter (14 vs. 37 months, <jats:italic>p<\/jats:italic>&lt;0.001) in the stem cell than in the anti-TNF group. Three patients experienced fistula recurrence, all in the stem cell group.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Medical treatment using anti-TNF agents and auto-ASC transplantation are feasible treatment options after seton placement for Crohn\u2019s perianal fistula. However, the closure rate was significantly faster and the time to closure significantly shorter in patients who underwent auto-ASC transplantation than medical treatment.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Trial registration<\/jats:title>\n                <jats:p>This study was retrospectively registered and approved by the Institutional Review Board of Asan Medical Center, number <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/eirb.amc.seoul.kr\/\">2020-1059<\/jats:ext-link>.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13287-021-02484-6","type":"journal-article","created":{"date-parts":[[2021,7,13]],"date-time":"2021-07-13T13:03:26Z","timestamp":1626181406000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Comparative perianal fistula closure rates following autologous adipose tissue-derived stem cell transplantation or treatment with anti-tumor necrosis factor agents after seton placement in patients with Crohn\u2019s disease: a retrospective observational study"],"prefix":"10.1186","volume":"12","author":[{"given":"Min Young","family":"Park","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3196-8423","authenticated-orcid":false,"given":"Yong Sik","family":"Yoon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jong Lyul","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sang Hyoung","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Byong Duk","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suk-Kyun","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chang Sik","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,7,13]]},"reference":[{"key":"2484_CR1","doi-asserted-by":"crossref","unstructured":"Steinhart AH, Panaccione R, Targownik L, Bressler B, Khanna R, Marshall JK, Afif W, Bernstein CN, Bitton A, Borgaonkar M: 0. Inflammatory bowel diseases 2019, 25(1):1-13.","DOI":"10.1093\/ibd\/izy247"},{"issue":"10080","key":"2484_CR2","doi-asserted-by":"publisher","first-page":"1741","DOI":"10.1016\/S0140-6736(16)31711-1","volume":"389","author":"J Torres","year":"2017","unstructured":"Torres J, Mehandru S, Colombel J-F, Peyrin-Biroulet L. Crohn's disease. Lancet. 2017;389(10080):1741\u201355.","journal-title":"Lancet"},{"issue":"34","key":"2484_CR3","doi-asserted-by":"publisher","first-page":"4263","DOI":"10.3748\/wjg.15.4263","volume":"15","author":"C Taxonera","year":"2009","unstructured":"Taxonera C, Schwartz DA, Garc\u00eda-Olmo D. Emerging treatments for complex perianal fistula in Crohn\u2019s disease. World J Gastroenterol: WJG. 2009;15(34):4263.","journal-title":"World J Gastroenterol: WJG"},{"issue":"1","key":"2484_CR4","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1007\/BF02603444","volume":"24","author":"DR Williams","year":"1981","unstructured":"Williams DR, Coller JA, Corman ML, Nugent FW, Veidenheimer MC. Anal complications in Crohn's disease. Dis Colon Rectum. 1981;24(1):22\u20134.","journal-title":"Dis Colon Rectum"},{"issue":"2","key":"2484_CR5","doi-asserted-by":"publisher","first-page":"147","DOI":"10.5217\/ir.2017.15.2.147","volume":"15","author":"JP Im","year":"2017","unstructured":"Im JP. Adalimumab or infliximab: which is better for perianal fistula in Crohn's disease? Intestinal Research. 2017;15(2):147.","journal-title":"Intestinal Research"},{"issue":"11","key":"2484_CR6","doi-asserted-by":"publisher","first-page":"1410","DOI":"10.1093\/ecco-jcc\/jjz081","volume":"13","author":"SH Park","year":"2019","unstructured":"Park SH, Kim Y-J, Rhee KH, Kim Y-H, Hong SN, Kim KH, et al. A 30-year trend analysis in the epidemiology of inflammatory bowel disease in the Songpa-Kangdong District of Seoul, Korea in 1986\u20132015. J Crohn's Colitis. 2019;13(11):1410\u20137.","journal-title":"J Crohn's Colitis"},{"issue":"6","key":"2484_CR7","doi-asserted-by":"publisher","first-page":"1629","DOI":"10.1016\/S0016-5085(03)00392-5","volume":"124","author":"DH Present","year":"2003","unstructured":"Present DH. Crohn\u2019s fistula: current concepts in management. Gastroenterology. 2003;124(6):1629\u201335.","journal-title":"Gastroenterology"},{"issue":"2","key":"2484_CR8","doi-asserted-by":"publisher","first-page":"132","DOI":"10.7326\/0003-4819-123-2-199507150-00009","volume":"123","author":"DC Pearson","year":"1995","unstructured":"Pearson DC, May GR, Fick GH, Sutherland LR. Azathioprine and 6-mercaptopurine in Crohn disease: a meta-analysis. Ann Intern Med. 1995;123(2):132\u201342.","journal-title":"Ann Intern Med"},{"issue":"9","key":"2484_CR9","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1136\/gutjnl-2013-306709","volume":"63","author":"KB Gecse","year":"2014","unstructured":"Gecse KB, Bemelman W, Kamm MA, Stoker J, Khanna R, Ng SC, et al. A global consensus on the classification, diagnosis and multidisciplinary treatment of perianal fistulising Crohn's disease. Gut. 2014;63(9):1381\u201392.","journal-title":"Gut"},{"issue":"9","key":"2484_CR10","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1056\/NEJMoa030815","volume":"350","author":"BE Sands","year":"2004","unstructured":"Sands BE, Anderson FH, Bernstein CN, Chey WY, Feagan BG, Fedorak RN, et al. Infliximab maintenance therapy for fistulizing Crohn's disease. N Engl J Med. 2004;350(9):876\u201385.","journal-title":"N Engl J Med"},{"issue":"12","key":"2484_CR11","doi-asserted-by":"publisher","first-page":"1705","DOI":"10.1136\/gut.34.12.1705","volume":"34","author":"S Murch","year":"1993","unstructured":"Murch S, Braegger C, Walker-Smith J, MacDonald T. Location of tumour necrosis factor alpha by immunohistochemistry in chronic inflammatory bowel disease. Gut. 1993;34(12):1705\u20139.","journal-title":"Gut"},{"key":"2484_CR12","unstructured":"Yapali S, Over Hamzaoglu H: Anti-TNF treatment in inflammatory bowel disease. Annals of gastroenterology 2007."},{"issue":"2","key":"2484_CR13","doi-asserted-by":"publisher","first-page":"151","DOI":"10.5217\/ir.2019.09154","volume":"18","author":"E Mizoguchi","year":"2020","unstructured":"Mizoguchi E, Low D, Ezaki Y, Okada T. Recent updates on the basic mechanisms and pathogenesis of inflammatory bowel diseases in experimental animal models. Intestinal Res. 2020;18(2):151.","journal-title":"Intestinal Res"},{"issue":"3","key":"2484_CR14","doi-asserted-by":"publisher","first-page":"285","DOI":"10.5217\/ir.2019.00026","volume":"17","author":"C Ooi","year":"2019","unstructured":"Ooi C, Hilmi I, Banerjee R, Chuah S, Ng S, Wei S, et al. Best practices on immunomodulators and biologic agents for ulcerative colitis and Crohn's disease in Asia. Intestinal Research. 2019;17(3):285\u2013310.","journal-title":"Intestinal Research"},{"issue":"2","key":"2484_CR15","first-page":"211","volume":"10","author":"N Avdagic","year":"2013","unstructured":"Avdagic N, Babic N, Seremet M, Delic-Sarac M, Drace Z, Denjalic A, et al. Tumor necrosis factor-alpha serum level in assessment of disease activity in inflammatory bowel diseases. Med Glas (Zenica). 2013;10(2):211\u20136.","journal-title":"Med Glas (Zenica)"},{"issue":"8785","key":"2484_CR16","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/0140-6736(92)90999-J","volume":"339","author":"CP Braegger","year":"1992","unstructured":"Braegger CP, Nicholls S, Murch S, MacDonald T, Stephens S. Tumour necrosis factor alpha in stool as a marker of intestinal inflammation. Lancet. 1992;339(8785):89\u201391.","journal-title":"Lancet"},{"issue":"2","key":"2484_CR17","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1517\/13543784.2016.1126247","volume":"25","author":"M Berns","year":"2016","unstructured":"Berns M, Hommes DW. Anti-TNF-\u03b1 therapies for the treatment of Crohn\u2019s disease: the past, present and future. Expert Opin Investig Drugs. 2016;25(2):129\u201343.","journal-title":"Expert Opin Investig Drugs"},{"key":"2484_CR18","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.cyto.2016.08.014","volume":"101","author":"H Mitoma","year":"2018","unstructured":"Mitoma H, Horiuchi T, Tsukamoto H, Ueda N. Molecular mechanisms of action of anti-TNF-\u03b1 agents\u2013comparison among therapeutic TNF-\u03b1 antagonists. Cytokine. 2018;101:56\u201363.","journal-title":"Cytokine"},{"issue":"7","key":"2484_CR19","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1111\/codi.13311","volume":"18","author":"EJ de Groof","year":"2016","unstructured":"de Groof EJ, Sahami S, Lucas C, Ponsioen CY, Bemelman WA, Buskens CJ. Treatment of perianal fistula in Crohn's disease: a systematic review and meta\u2010analysis comparing seton drainage and anti\u2010tumour necrosis factor treatment. Color Dis. 2016;18(7):667\u201375.","journal-title":"Color Dis"},{"issue":"5","key":"2484_CR20","first-page":"299","volume":"53","author":"G Sciaudone","year":"2010","unstructured":"Sciaudone G, Di Stazio C, Limongelli P, Guadagni I, Pellino G, Riegler G, et al. Treatment of complex perianal fistulas in Crohn disease: infliximab, surgery or combined approach. Can J Surg. 2010;53(5):299.","journal-title":"Can J Surg"},{"issue":"1","key":"2484_CR21","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1111\/j.1365-2036.2010.04486.x","volume":"33","author":"P Tozer","year":"2011","unstructured":"Tozer P, Burling D, Gupta A, Phillips R, Hart A. Medical, surgical and radiological management of perianal Crohn\u2019s fistulas. Aliment Pharmacol Ther. 2011;33(1):5\u201322.","journal-title":"Aliment Pharmacol Ther"},{"issue":"7","key":"2484_CR22","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1111\/apt.12906","volume":"40","author":"N Yassin","year":"2014","unstructured":"Yassin N, Askari A, Warusavitarne J, Faiz O, Athanasiou T, Phillips R, et al. Systematic review: the combined surgical and medical treatment of fistulising perianal Crohn's disease. Aliment Pharmacol Ther. 2014;40(7):741\u20139.","journal-title":"Aliment Pharmacol Ther"},{"issue":"5","key":"2484_CR23","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1007\/s00384-003-0490-3","volume":"18","author":"D Garcia-Olmo","year":"2003","unstructured":"Garcia-Olmo D, Garcia-Arranz M, Garcia LG, Cuellar ES, Blanco IF, Prianes LA, et al. Autologous stem cell transplantation for treatment of rectovaginal fistula in perianal Crohn's disease: a new cell-based therapy. Int J Color Dis. 2003;18(5):451\u20134.","journal-title":"Int J Color Dis"},{"issue":"5","key":"2484_CR24","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1111\/codi.13223","volume":"18","author":"K Park","year":"2016","unstructured":"Park K, Ryoo SB, Kim J, Kim T, Baik S, Kim H, et al. Allogeneic adiposederived stem cells for the treatment of perianal fistula in Crohn's disease: a pilot clinical trial. Color Dis. 2016;18(5):468\u201376.","journal-title":"Color Dis"},{"issue":"1","key":"2484_CR25","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1007\/DCR.0b013e3181973487","volume":"52","author":"D Garcia-Olmo","year":"2009","unstructured":"Garcia-Olmo D, Herreros D, Pascual I, Pascual JA, Del-Valle E, Zorrilla J, et al. Expanded adipose-derived stem cells for the treatment of complex perianal fistula: a phase II clinical trial. Dis Colon Rectum. 2009;52(1):79\u201386.","journal-title":"Dis Colon Rectum"},{"issue":"5","key":"2484_CR26","doi-asserted-by":"publisher","first-page":"532","DOI":"10.5966\/sctm.2014-0199","volume":"4","author":"YB Cho","year":"2015","unstructured":"Cho YB, Park KJ, Yoon SN, Song KH, Kim DS, Jung SH, et al. Long\u2010term results of adipose\u2010derived stem cell therapy for the treatment of Crohn's fistula. Stem Cells Transl Med. 2015;4(5):532\u20137.","journal-title":"Stem Cells Transl Med"},{"issue":"1","key":"2484_CR27","doi-asserted-by":"publisher","first-page":"25","DOI":"10.4110\/in.2017.17.1.25","volume":"17","author":"DH Kim","year":"2017","unstructured":"Kim DH, Cheon JH. Pathogenesis of inflammatory bowel disease and recent advances in biologic therapies. Immune Network. 2017;17(1):25.","journal-title":"Immune Network"},{"issue":"5","key":"2484_CR28","doi-asserted-by":"publisher","first-page":"558","DOI":"10.3904\/kjim.2014.29.5.558","volume":"29","author":"K-M Lee","year":"2014","unstructured":"Lee K-M, Lee JM. Crohn's disease in Korea: past, present, and future. The Korean J Intern Med. 2014;29(5):558.","journal-title":"The Korean J Intern Med"},{"issue":"10","key":"2484_CR29","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.3109\/00365521.2010.497936","volume":"45","author":"BD Ye","year":"2010","unstructured":"Ye BD, Yang S-K, Cho YK, Park SH, Yang D-H, Yoon SM, et al. Clinical features and long-term prognosis of Crohn's disease in Korea. Scand J Gastroenterol. 2010;45(10):1178\u201385.","journal-title":"Scand J Gastroenterol"},{"issue":"33","key":"2484_CR30","doi-asserted-by":"publisher","first-page":"11525","DOI":"10.3748\/wjg.v20.i33.11525","volume":"20","author":"SJ Park","year":"2014","unstructured":"Park SJ, Kim WH, Cheon JH. Clinical characteristics and treatment of inflammatory bowel disease: a comparison of eastern and Western perspectives. World J Gastroenterol: WJG. 2014;20(33):11525.","journal-title":"World J Gastroenterol: WJG"},{"issue":"8","key":"2484_CR31","doi-asserted-by":"publisher","first-page":"2102","DOI":"10.1007\/s10620-017-4640-9","volume":"62","author":"YS Jung","year":"2017","unstructured":"Jung YS, Han M, Kim WH, Park S, Cheon JH. Incidence and clinical outcomes of inflammatory bowel disease in South Korea, 2011\u20132014: a nationwide population-based study. Dig Dis Sci. 2017;62(8):2102\u201312.","journal-title":"Dig Dis Sci"},{"issue":"sup170","key":"2484_CR32","doi-asserted-by":"publisher","first-page":"2","DOI":"10.3109\/00365528909091339","volume":"24","author":"J Lennard-Jones","year":"1989","unstructured":"Lennard-Jones J. Classification of inflammatory bowel disease. Scand J Gastroenterol. 1989;24(sup170):2\u20136.","journal-title":"Scand J Gastroenterol"},{"issue":"Suppl A","key":"2484_CR33","doi-asserted-by":"publisher","first-page":"5A","DOI":"10.1155\/2005\/269076","volume":"19","author":"MS Silverberg","year":"2005","unstructured":"Silverberg MS, Satsangi J, Ahmad T, Arnott ID, Bernstein CN, Brant SR, et al. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a working party of the 2005 Montreal world congress of gastroenterology. Can J Gastroenterol. 2005;19(Suppl A):5A\u201336A.","journal-title":"Can J Gastroenterol"},{"issue":"1","key":"2484_CR34","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/bjs.1800630102","volume":"63","author":"AG Parks","year":"1976","unstructured":"Parks AG, Gordon PH, Hardcastle JD. A classification of fistula-in-ano. Br J Surg. 1976;63(1):1\u201312.","journal-title":"Br J Surg"},{"issue":"2","key":"2484_CR35","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1053\/j.gastro.2005.11.030","volume":"130","author":"SB Hanauer","year":"2006","unstructured":"Hanauer SB, Sandborn WJ, Rutgeerts P, Fedorak RN, Lukas M, MacIntosh D, et al. Human anti\u2013tumor necrosis factor monoclonal antibody (adalimumab) in Crohn\u2019s disease: the CLASSIC-I trial. Gastroenterology. 2006;130(2):323\u201333.","journal-title":"Gastroenterology"},{"issue":"9","key":"2484_CR36","doi-asserted-by":"publisher","first-page":"1232","DOI":"10.1136\/gut.2006.106781","volume":"56","author":"WJ Sandborn","year":"2007","unstructured":"Sandborn WJ, Hanauer SB, Rutgeerts P, Fedorak RN, Lukas M, MacIntosh DG, et al. Adalimumab for maintenance treatment of Crohn\u2019s disease: results of the CLASSIC II trial. Gut. 2007;56(9):1232\u20139.","journal-title":"Gut"},{"issue":"8","key":"2484_CR37","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1016\/j.cgh.2012.12.042","volume":"11","author":"G Bouguen","year":"2013","unstructured":"Bouguen G, Siproudhis L, Gizard E, Wallenhorst T, Billioud V, Bretagne JF, et al. Long-term outcome of perianal fistulizing Crohn's disease treated with infliximab. Clin Gastroenterol Hepatol. 2013;11(8):975\u2013981. e974.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"11","key":"2484_CR38","doi-asserted-by":"publisher","first-page":"1754","DOI":"10.1007\/s10350-007-9077-3","volume":"50","author":"WB Gaertner","year":"2007","unstructured":"Gaertner WB, Decanini A, Mellgren A, Lowry AC, Goldberg SM, Madoff RD, et al. Does infliximab infusion impact results of operative treatment for Crohn\u2019s perianal fistulas? Dis Colon Rectum. 2007;50(11):1754\u201360.","journal-title":"Dis Colon Rectum"},{"issue":"2","key":"2484_CR39","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1007\/BF02090211","volume":"39","author":"DH Present","year":"1994","unstructured":"Present DH, Lichtiger S. Efficacy of cyclosporine in treatment of fistula of Crohn's disease. Dig Dis Sci. 1994;39(2):374\u201380.","journal-title":"Dig Dis Sci"},{"issue":"5","key":"2484_CR40","first-page":"646","volume":"88","author":"SB Hanauer","year":"1993","unstructured":"Hanauer SB, Smith MB. Rapid closure of Crohn's disease fistulas with continuous intravenous cyclosporin A. Am J Gastroenterol. 1993;88(5):646.","journal-title":"Am J Gastroenterol"},{"issue":"4","key":"2484_CR41","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1097\/00054725-199911000-00001","volume":"5","author":"PW Lowry","year":"1999","unstructured":"Lowry PW, Weaver AL, Tremaine WJ, Sandborn WJ. Combination therapy with oral tacrolimus (FK506) and azathioprine or 6-mercaptopurine for treatment-refractory Crohn's disease perianal fistulae. Inflamm Bowel Dis. 1999;5(4):239\u201345.","journal-title":"Inflamm Bowel Dis"},{"issue":"15","key":"2484_CR42","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1056\/NEJM199710093371502","volume":"337","author":"SR Targan","year":"1997","unstructured":"Targan SR, Hanauer SB, Van Deventer SJ, Mayer L, Present DH, Braakman T, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor \u03b1 for Crohn's disease. N Engl J Med. 1997;337(15):1029\u201336.","journal-title":"N Engl J Med"},{"issue":"18","key":"2484_CR43","doi-asserted-by":"publisher","first-page":"1398","DOI":"10.1056\/NEJM199905063401804","volume":"340","author":"DH Present","year":"1999","unstructured":"Present DH, Rutgeerts P, Targan S, Hanauer SB, Mayer L, Van Hogezand R, et al. Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med. 1999;340(18):1398\u2013405.","journal-title":"N Engl J Med"},{"issue":"7","key":"2484_CR44","doi-asserted-by":"publisher","first-page":"1416","DOI":"10.1007\/s10350-005-0052-6","volume":"48","author":"D Garc\u00eda-Olmo","year":"2005","unstructured":"Garc\u00eda-Olmo D, Garc\u00eda-Arranz M, Herreros D, Pascual I, Peiro C, Rodr\u00edguez-Montes JA. A phase I clinical trial of the treatment of Crohn\u2019s fistula by adipose mesenchymal stem cell transplantation. Dis Colon Rectum. 2005;48(7):1416\u201323.","journal-title":"Dis Colon Rectum"},{"key":"2484_CR45","doi-asserted-by":"crossref","unstructured":"Garcia-Olmo D, Guadalajara H, Rubio-Perez I, Herreros MD, de la Quintana P, Garcia-Arranz M: Recurrent anal fistulae: limited surgery supported by stem cells. World J Gastroenterol: WJG 2015, 21(11):3330.","DOI":"10.3748\/wjg.v21.i11.3330"},{"key":"2484_CR46","doi-asserted-by":"crossref","unstructured":"Lee WY, Park KJ, Cho YB, Yoon SN, Song KH, Kim DS, Jung SH, Kim M, Yoo HW, Kim I: Autologous adipose tissue\u2010derived stem cells treatment demonstrated favorable and sustainable therapeutic effect for Crohn's fistula. Stem Cells 2013, 31(11):2575-2581.","DOI":"10.1002\/stem.1357"},{"issue":"6","key":"2484_CR47","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1002\/bjs.6608","volume":"96","author":"P Van Koperen","year":"2009","unstructured":"Van Koperen P, Safiruddin F, Bemelman W, Slors J. Outcome of surgical treatment for fistula in ano in Crohn's disease. Br J Surg. 2009;96(6):675\u20139.","journal-title":"Br J Surg"},{"issue":"3","key":"2484_CR48","doi-asserted-by":"publisher","first-page":"311","DOI":"10.5217\/ir.2019.00043","volume":"17","author":"H Shimizu","year":"2019","unstructured":"Shimizu H, Suzuki K, Watanabe M, Okamoto R. Stem cell-based therapy for inflammatory bowel disease. Intestinal Res. 2019;17(3):311.","journal-title":"Intestinal Res"}],"container-title":["Stem Cell Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13287-021-02484-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13287-021-02484-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13287-021-02484-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,13]],"date-time":"2021-07-13T14:12:14Z","timestamp":1626185534000},"score":1,"resource":{"primary":{"URL":"https:\/\/stemcellres.biomedcentral.com\/articles\/10.1186\/s13287-021-02484-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,13]]},"references-count":48,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["2484"],"URL":"https:\/\/doi.org\/10.1186\/s13287-021-02484-6","relation":{},"ISSN":["1757-6512"],"issn-type":[{"value":"1757-6512","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,13]]},"assertion":[{"value":"9 April 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 June 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 July 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This retrospective study was performed following the ethical policies of the Asan Medical Center in Seoul, South Korea, and was approved by the Institutional Review Board of Asan Medical Center (No. 2020-1059). Informed consent was waived because of the retrospective observational nature of this study, involving previously collected data.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"401"}}